缩小放疗照射体积对胶质母细胞瘤放化疗患者淋巴细胞减少症的影响
该研究纳入2007至2016年接受放疗联合替莫唑胺治疗的210例幕上非转移性胶质母细胞瘤患者,比较标准野放疗(SFRT,164例)与2015年后实施的小野放疗(LFRT,46例)对急性重度淋巴细胞减少症(ASL)的影响。
要点
- 小野放疗与放化疗后淋巴细胞减少程度较轻相关,且不损害PFS或OS。
- 脑V25 Gy是急性重度淋巴细胞减少症的独立剂量学预测因子。
- 急性重度淋巴细胞减少症是总生存的独立预测因子。
核心结论
- 小野放疗与放疗联合替莫唑胺后较少的淋巴细胞减少相关,且不 adverse 影响无进展生存或总生存。
- 脑V25 Gy被证实为急性重度淋巴细胞减少症的重要剂量学预测因子。
研究设计与样本
- 研究纳入2007至2016年接受放疗联合替莫唑胺治疗且有总淋巴细胞计数实验室数据的210例幕上非转移性胶质母细胞瘤患者。
- 2015年前164例接受标准野放疗,此后46例实施小野放疗以缩小治疗体积。
- 采用Cox回归进行总生存多因素分析,逻辑回归分析急性重度淋巴细胞减少症,并进行倾向性评分匹配。
主要发现
- 小野放疗组肿瘤总体积高于标准野放疗组,但脑剂量体积参数较低,包括V25 Gy(分别为41% vs 53%,P<.01)。
- 第12周总淋巴细胞计数小野放疗组显著高于标准野放疗组(中位数:1100 cells/μL vs 900 cells/μL,P=.02)。
- 多因素分析显示急性重度淋巴细胞减少症是总生存的独立预测因子,脑V25 Gy是急性重度淋巴细胞减少症的独立预测因子。
- 3个月时急性重度淋巴细胞减少症发生率小野放疗组为15.5%,标准野放疗组为33.8%(P=.12)。
- 倾向性匹配45对患者后,无进展生存(中位数:5.9 vs 6.2个月,P=.58)和总生存(中位数:16.2 vs 13.9个月,P=.69)无显著差异。
关键数值与推荐
- 急性重度淋巴细胞减少症定义为开始放疗后3个月内(至第12周)任何总淋巴细胞计数<500 cells/μL。
临床怎么用
- 在胶质母细胞瘤放化疗中可考虑采用小野放疗以降低淋巴细胞减少风险,且不牺牲生存获益。
- 计划设计时应关注脑V25 Gy作为可优化的剂量学参数以降低急性重度淋巴细胞减少症风险。
局限性
- 小野放疗与标准野放疗组间急性重度淋巴细胞减少症发生率差异未达统计学显著性(P=.12)。
- 研究为单中心回顾性设计,小野放疗样本量较小(46例),倾向性匹配仅45对。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate whether reduction in glioblastoma radiation treatment volume can reduce risk of acute severe lymphopenia (ASL). METHODS AND MATERIALS: A total of 210 patients with supratentorial/nonmetastatic glioblastoma were treated with radiation therapy (RT) plus temozolomide from 2007 to 2016 and had laboratory data on total lymphocyte counts. Before 2015, 164 patients were treated with standard-field RT (SFRT), and limited-field RT (LFRT) was implemented thereafter for 46 patients to reduce treatment volume. Total lymphocyte counts were evaluated at baseline, during RT, and at approximately week 12 from initiating RT. Acute severe lymphopenia was defined as any total lymphocyte count < 500 cells/μL within 3 months (by week 12) of initiating RT. Multivariate analysis for overall survival (OS) was performed with Cox regression and with logistic regression for ASL. Propensity score matching was performed to adjust for variability between cohorts. Acute severe lymphopenia, progression-free survival (PFS), and OS were compared using the Kaplan-Meier method. RESULTS: Limited-field RT patients had higher gross tumor volume than SFRT patients yet lower brain dose-volume parameters, including volume receiving 25 Gy (V25 Gy: 41% vs 53%, respectively, P < .01). Total lymphocyte count at week 12 was significantly higher for LFRT than for SFRT (median: 1100 cells/μL vs 900 cells/μL, respectively, P = .02). On multivariate analysis, ASL was an independent predictor of OS, and brain V25 Gy was an independent predictor of ASL. The ASL rate at 3 months was 15.5% for LFRT and 33.8% for SFRT (P = .12). In a propensity-matched comparison of 45 pairs of LFRT and SFRT patients, PFS (median: 5.9 vs 6.2 months, respectively, P = .58) and OS (median: 16.2 vs 13.9 months, respectively, P = .69) were not significantly different. CONCLUSIONS: Limited-field RT is associated with less lymphopenia after RT plus temozolomide and does not adversely affect PFS or OS. Brain V25 Gy is confirmed as an important dosimetric predictor for ASL.
引用
- Rudra S, Hui C, Rao YJ, et al. Effect of Radiation Treatment Volume Reduction on Lymphopenia in Patients Receiving Chemoradiotherapy for Glioblastoma. Int J Radiat Oncol Biol Phys. 2018. PMID: 29502931. doi:10.1016/j.ijrobp.2018.01.069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。